Aspire Biopharma Holdings, Inc.
ASBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 45.5% | – | – | – |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 0% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -95,337.1% | – | – | – |
| EPS Diluted | -0.037 | -0.04 | -0.33 | -0.25 |
| % Growth | 7% | 87.8% | -32% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |